<DOC>
	<DOC>NCT01280786</DOC>
	<brief_summary>This is a phase 1 study to test the safety of escalating doses of elesclomol sodium given to patients with advanced myeloid leukemia.</brief_summary>
	<brief_title>Study Elesclomol Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia</brief_title>
	<detailed_description>This aim of this study is to determine the safety and tolerability of elesclomol sodium at escalating doses (ultimately identifying the maximum tolerated dose) when administered to patients with advanced myeloid leukemia.</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Myeloid</mesh_term>
	<mesh_term>Leukemia, Myeloid, Acute</mesh_term>
	<criteria>Adults with cytologically confirmed Acute Myeloid Leukemia (AML) that has relapsed after the completion of induction and/or consolidation therapy or has failed to respond to standard induction therapy ECOG performance status of 02 Acceptable organ and marrow function during the screening period as defined by the protocol Reliable venous access suitable for study drug infusions Significant cardiovascular disease Candidates for hematopoietic stem cell transplant Women who are pregnant or breastfeeding Prior treatment with chronic immunosuppressants Other clinically significant uncontrolled conditions</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>AML</keyword>
	<keyword>leukemia</keyword>
	<keyword>relapsed or refractory AML</keyword>
</DOC>